Description

Product details

CLANARIZINE DOM represents an advanced pharmaceutical combination that brings together two potent therapeutic agents—Cinnarizine and Domperidone—in a single convenient tablet formulation. This innovative combination medication addresses multiple aspects of vestibular disorders, motion sickness, and associated nausea and vomiting, providing comprehensive relief for patients suffering from these debilitating conditions. Manufactured under stringent quality control standards, CLANARIZINE DOM offers a synergistic approach to managing symptoms that significantly impact quality of life and daily functioning.The combination of Cinnarizine and Domperidone in CLANARIZINE DOM is based on sound pharmacological principles. While Cinnarizine works primarily on the vestibular system to reduce dizziness and vertigo, Domperidone acts as an effective antiemetic to control nausea and vomiting. Together, these two active ingredients provide more comprehensive symptom control than either agent alone, making CLANARIZINE DOM an excellent choice for patients experiencing vestibular disturbances accompanied by gastrointestinal symptoms.This combination therapy is particularly valuable because vertigo, dizziness, and motion sickness are frequently accompanied by nausea and vomiting. Patients suffering from these conditions often find that addressing only one aspect of their symptoms provides insufficient relief. CLANARIZINE DOM's dual-action formula tackles both the underlying vestibular dysfunction and the accompanying gastrointestinal distress, offering patients a more complete therapeutic solution that improves both comfort and functional capacity.Understanding the Active IngredientsCinnarizine is a calcium channel blocker with specific antihistaminic and vestibular suppressant properties. Unlike systemic calcium channel blockers used for cardiovascular conditions, Cinnarizine selectively acts on the blood vessels in the inner ear and brain, improving blood flow to these areas. This enhanced circulation helps reduce the frequency and severity of vertigo attacks while also preventing motion sickness. Cinnarizine also possesses mild antihistaminic effects that contribute to its anti-nausea properties, though this is not its primary mechanism of action.The medication works by blocking calcium channels in the vestibular system, which helps stabilize the sensory organs responsible for balance. By reducing the excessive stimulation of the vestibular apparatus, Cinnarizine decreases the sensation of spinning or imbalance that characterizes vertigo. Additionally, its vasodilatory effects improve microcirculation in the inner ear, which can be beneficial for conditions where reduced blood flow contributes to symptoms.Domperidone is a peripheral dopamine antagonist that acts primarily as a prokinetic and antiemetic agent. Unlike some antiemetic medications that cross the blood-brain barrier and cause sedation or extrapyramidal side effects, Domperidone works predominantly in the peripheral nervous system. It blocks dopamine receptors in the chemoreceptor trigger zone (CTZ) located outside the blood-brain barrier, effectively preventing nausea and vomiting without causing significant central nervous system effects.Domperidone also enhances gastrointestinal motility by promoting coordinated contractions of the stomach and upper small intestine. This prokinetic effect helps empty the stomach more efficiently, reducing feelings of fullness, bloating, and discomfort that often accompany vestibular disorders. By accelerating gastric emptying, Domperidone also reduces the likelihood of gastroesophageal reflux, which can exacerbate nausea in some patients.The combination of these two medications in CLANARIZINE DOM creates a complementary therapeutic effect. While Cinnarizine addresses the vestibular component of dizziness and vertigo, Domperidone manages the gastrointestinal symptoms that frequently accompany these conditions. This dual approach provides more comprehensive symptom relief and improves overall treatment outcomes compared to monotherapy with either agent alone.Clinical Applications and UsesCLANARIZINE DOM is indicated for a wide range of conditions characterized by vertigo, dizziness, and associated nausea. Understanding these clinical applications helps healthcare providers select appropriate candidates for this combination therapy.Vestibular Disorders: The primary indication for CLANARIZINE DOM includes various vestibular disorders that cause vertigo and imbalance. These conditions include Ménière's disease, benign paroxysmal positional vertigo (BPPV), vestibular neuritis, and labyrinthitis. Patients with these disorders experience episodes of spinning sensation, loss of balance, and often severe nausea. CLANARIZINE DOM helps reduce the frequency and intensity of vertigo attacks while controlling the accompanying gastrointestinal symptoms.Motion Sickness: CLANARIZINE DOM is highly effective for preventing and treating motion sickness, whether related to travel by car, boat, airplane, or amusement park rides. The medication can be taken prophylactically before travel or at the onset of symptoms. The combination is particularly useful for individuals who experience severe nausea and vomiting with motion sickness, as Domperidone provides powerful antiemetic effects that complement Cinnarizine's anti-motion-sickness properties.Migraine-Associated Vertigo: Many patients with migraines experience vestibular symptoms, including dizziness, vertigo, and motion sensitivity, either during migraine attacks or as independent episodes. CLANARIZINE DOM can help manage these vestibular manifestations of migraine, reducing both the vertigo and the nausea that often accompany migraine headaches.Post-Concussion Syndrome: Following head injuries, some patients develop persistent dizziness, balance problems, and nausea as part of post-concussion syndrome. CLANARIZINE DOM may provide symptomatic relief for these patients during their recovery period, though it should be used as part of a comprehensive treatment approach that includes rest, gradual return to activities, and vestibular rehabilitation when appropriate.Cerebrovascular Insufficiency: In older adults with reduced blood flow to the brain, symptoms such as dizziness, vertigo, tinnitus (ringing in the ears), and cognitive difficulties may develop. Cinnarizine's vasodilatory properties can improve cerebral circulation, potentially reducing these symptoms. The addition of Domperidone helps manage any associated nausea.Radiation-Induced or Chemotherapy-Induced Nausea: While not a primary indication, some healthcare providers use CLANARIZINE DOM as adjunctive therapy for patients undergoing cancer treatment who experience both nausea and dizziness. Domperidone's strong antiemetic properties are particularly valuable in this context.Key Benefits of CLANARIZINE DOMThe unique combination of Cinnarizine and Domperidone in CLANARIZINE DOM offers numerous advantages that make it a preferred choice for managing vestibular disorders and associated symptoms.Comprehensive Symptom Control: The primary benefit of CLANARIZINE DOM is its ability to address multiple symptoms simultaneously. Rather than requiring patients to take separate medications for vertigo and nausea, this combination provides unified treatment in a single tablet. This comprehensive approach improves symptom control across the full spectrum of vestibular disorder manifestations, from the spinning sensation to the gastrointestinal distress that often accompanies it.Improved Patient Compliance: Taking multiple medications can be burdensome, particularly for patients who feel dizzy or nauseated. CLANARIZINE DOM simplifies the treatment regimen by combining two medications in one tablet, making it easier for patients to adhere to their prescribed therapy. Better compliance translates to better outcomes, as consistent medication use is essential for managing chronic vestibular conditions.Synergistic Therapeutic Effects: The combination of Cinnarizine and Domperidone creates synergistic effects that enhance overall efficacy. While Cinnarizine reduces vestibular stimulation and improves inner ear blood flow, Domperidone prevents nausea and promotes gastric emptying. This dual action addresses both the cause and consequences of vestibular dysfunction, providing more complete relief than either medication alone.Reduced Central Nervous System Side Effects: Because Domperidone works primarily in the peripheral nervous system rather than crossing the blood-brain barrier extensively, CLANARIZINE DOM causes less sedation and fewer cognitive effects compared to some alternative antiemetic medications. This allows patients to maintain better alertness and function during treatment, which is particularly important for those who need to continue working or performing daily activities.Enhanced Quality of Life: Vertigo and chronic dizziness significantly impair quality of life, limiting mobility, social interactions, and occupational functioning. The nausea and vomiting that accompany these conditions add another layer of disability. By effectively controlling both vestibular and gastrointestinal symptoms, CLANARIZINE DOM helps restore patients' ability to engage in normal activities, improving overall life satisfaction and functional independence.Fast Onset of Action: CLANARIZINE DOM provides relatively rapid symptom relief, with many patients experiencing improvement within 30 minutes to 2 hours after taking the medication. This quick onset is particularly valuable for acute episodes of vertigo or when taking the medication prophylactically before situations that might trigger motion sickness.Suitable for Long-Term Use: For patients with chronic vestibular disorders requiring ongoing treatment, CLANARIZINE DOM is generally safe for extended use when properly monitored by a healthcare provider. The medication maintains its effectiveness over time without significant tolerance development, making it suitable for long-term symptom management.Improved Gastric Emptying: The prokinetic effects of Domperidone benefit not only nausea but also other gastrointestinal symptoms such as early satiety, bloating, and upper abdominal discomfort. Patients with vestibular disorders often develop gastroparesis or delayed gastric emptying secondary to their condition, and Domperidone addresses this issue effectively.Vascular Benefits: Cinnarizine's ability to improve blood flow to the inner ear and brain provides additional benefits beyond symptom control. Enhanced microcirculation may support healing and recovery in conditions where vascular insufficiency contributes to vestibular dysfunction.Side Effects and Safety ConsiderationsLike all medications, CLANARIZINE DOM can cause side effects, though not everyone experiences them. Understanding potential adverse effects helps patients recognize when to seek medical attention and allows healthcare providers to monitor therapy appropriately.Common Side Effects:The most frequently reported side effect of CLANARIZINE DOM is drowsiness or sedation, occurring in approximately 10-20% of patients. This effect is primarily attributable to Cinnarizine's antihistaminic properties. Patients should avoid driving or operating machinery until they know how the medication affects them. Taking the medication at bedtime can minimize daytime drowsiness for some patients.Dry mouth is another common side effect, affecting roughly 10-15% of patients. This occurs due to anticholinergic effects and can be managed by sipping water frequently, chewing sugar-free gum, or using saliva substitutes if severe. Maintaining good oral hygiene is important to prevent dental problems associated with reduced saliva production.Mild gastrointestinal symptoms, including constipation, abdominal discomfort, or changes in bowel habits, may occur. While Domperidone promotes gastric emptying, it can occasionally alter bowel motility. These effects are usually mild and resolve with continued use or dose adjustment.

Other Specifications